| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
John P Brancaccio is Director at OKYO and has filed Form 4s across 3 companies. John P Brancaccio's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $63K at current prices.
The biggest single holding is OKYO (~$51K) as Director. Net of sales, the OKYO filings show accumulation of 16,670 shares.
John P Brancaccio has 26 Form 4 filings on record from March 2015 to July 2026, across 3 companies: Director at OKYO Pharma (OKYO), 2023–2026; Chairman at Hepion Pharmaceuticals (HEPA), 2016–2024; Former Director at Cardiff Oncology (CRDF), 2015–2022.
The 35 reported transactions were 16 option or other derivative awards, 9 other transactions, 7 open-market purchases and 2 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 5 purchases worth about $87K and no sales.
The largest open-market purchase was 3,000 shares of CRDF at an average $10.95 on March 22, 2021, about $33K. Twelve months later CRDF was down 76%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2023 | OKYO Okyo Pharma Ltd | Director | Buy | 16,670 | $1.50 | $25,005.00 | New | -15.1% | -48.2% | |
| Mar 22, 2021 | CRDF Cardiff Oncology, Inc. | Director | Buy | 3,000 | $10.95 | $32,850.00 | +32.4% | -26.4% | -75.9% | |
| Dec 2, 2020 | HEPA Hepion Pharmaceuticals, Inc. | Director | Buy | 7,000 | $1.53 | $10,710.00 | +87,500% | - | - | |
| May 14, 2020 | CRDF Cardiff Oncology, Inc. | Director | Buy | 6,993 | $1.43 | $9,999.99 | +308.5% | - | - | |
| Jun 8, 2018 | CRDF Cardiff Oncology, Inc. | Director | Buy | 10,000 | $0.80 | $8,000.00 | +23.2% | - | - |